We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $118.32 · 25 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Abbott Laboratories stock (US0028241000): Insider activity stays in focus - AD HOC NEWS
Abbott Laboratories stock (US0028241000): Insider activity stays in focus AD HOC NEWS
Is ACS’s Cologuard Endorsement Reshaping the Investment Case for Abbott Laboratories (ABT)? - Yahoo Finance
Is ACS’s Cologuard Endorsement Reshaping the Investment Case for Abbott Laboratories (ABT)? Yahoo Finance
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $115 - 富途牛牛
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $115 富途牛牛
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know Yahoo Finance
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 16. | After market close (AMC) | $1.28 | — | — | $12.53B | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.76 | — | — | $10.36B | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $2.38 | — | — | $30.98B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $1.44 | — | — | $20.34B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 04. 27. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 04. 20. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 04. 18. | Piper Sandler | — | Maintain | Overweight → Overweight | — | Piper Sandler: Overweight |
| 2026. 04. 17. | Oppenheimer | — | Maintain | Outperform → Outperform | — | Oppenheimer: Outperform |
| 2026. 04. 17. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 04. 17. | Benchmark | — | Maintain | Buy → Buy | — | Benchmark: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 6,388,828 | $655.94B | 0.56% | — | New position |
| 2 | SOROS FUND MANAGEMENT LLC | SOROS FUND MANAGEMENT LLC | 44,750 | $4.59B | 0.08% | — | New position |